ANIK (Anika Therapeutics) Cyclically Adjusted Book per Share: $20.29 (As of Mar. 2026)


ANIK Anika Therapeutics Inc ANIK
64 GF Score
Price $16.30
GF Value $20.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Cyclically Adjusted Book per Share?

Anika Therapeutics ANIK +2.96% 64 Cyclically Adjusted Book per Share is $20.29 as of Mar. 2026. GuruFocus rates ANIK with a GF Score™ of 64/100 and a GF Value™ of $20.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Anika Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $10.025. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $20.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Anika Therapeutics's average Cyclically Adjusted Book Growth Rate was -0.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 2.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Anika Therapeutics was 14.60% per year. The lowest was 2.40% per year. And the median was 12.85% per year.

As of today (2026-07-09), Anika Therapeutics's current stock price is $16.30. Anika Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $20.29. Anika Therapeutics's Cyclically Adjusted PB Ratio of today is 0.80.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Anika Therapeutics was 6.72. The lowest was 0.40. And the median was 2.50.


Anika Therapeutics  (NAS:ANIK) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Anika Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=16.30/20.29
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Anika Therapeutics was 6.72. The lowest was 0.40. And the median was 2.50.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Anika Therapeutics Cyclically Adjusted Book per Share Related Terms


Anika Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Cyclically Adjusted Book per Share Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.63 18.72 19.96 20.32 20.12

Anika Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.44 20.44 20.39 20.12 20.29

ANIK vs LFCR, DERM, ASRT: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted PB Ratio falls into.


ANIK
64GF Score
Anika Therapeutics Inc ANIK
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anika Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=10.025/330.2130*330.2130
=10.025

Current CPI (Mar. 2026) = 330.2130.

Anika Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 13.832 241.018 18.951
201609 14.672 241.428 20.068
201612 15.230 241.432 20.830
201703 15.696 243.801 21.259
201706 16.656 244.955 22.453
201709 17.275 246.819 23.112
201712 17.939 246.524 24.029
201803 17.889 249.554 23.671
201806 16.909 251.989 22.158
201809 17.962 252.439 23.496
201812 18.551 251.233 24.383
201903 18.930 254.202 24.590
201906 18.204 256.143 23.468
201909 19.741 256.759 25.389
201912 20.155 256.974 25.899
202003 20.686 258.115 26.464
202006 20.307 257.797 26.011
202009 20.020 260.280 25.399
202012 19.010 260.474 24.100
202103 19.258 264.877 24.008
202106 19.892 271.696 24.176
202109 20.093 274.310 24.188
202112 19.880 278.802 23.546
202203 19.685 287.504 22.609
202206 19.602 296.311 21.845
202209 19.507 296.808 21.702
202212 19.526 296.797 21.724
202303 18.831 301.836 20.601
202306 18.695 305.109 20.233
202309 18.480 307.789 19.826
202312 14.479 306.746 15.587
202403 14.070 312.332 14.876
202406 14.175 314.175 14.899
202409 12.241 315.301 12.820
202412 10.682 315.605 11.176
202503 10.352 319.799 10.689
202506 10.242 322.561 10.485
202509 10.180 324.800 10.350
202512 10.329 324.054 10.525
202603 10.025 330.213 10.025

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $20.29 mean?
Anika Therapeutics (ANIK) has a Cyclically Adjusted Book per Share of $20.29 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' Cyclically Adjusted Book per Share too high?
Anika Therapeutics' current Cyclically Adjusted Book per Share is $20.29. Overall, Anika Therapeutics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Cyclically Adjusted Book per Share compare to LFCR and DERM?
Anika Therapeutics' Cyclically Adjusted Book per Share of $20.29 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Cyclically Adjusted Book per Share is $20.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.58, compared to a current price of $16.30 — trading 20.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is $20.29. Anika Therapeutics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Cyclically Adjusted Book per Share is $20.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (ANIK) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of $16.30 is trading 20.8% below its estimated GF Value™ of $20.58. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for ANIK:

  • Cyclically Adjusted Book per Share: $20.29
  • GF Value™: $20.58 vs. price of $16.30 (20.8% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anika Therapeutics Business Description

Other Exchanges AKP:Germany
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
64GF Score

Get the complete analysis for ANIK

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.30
Price
$20.58
GF Value